XML 22 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Restatement of Previously Issued Financial Statements
4 Months Ended
Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]  
Restatement of Previously Issued Financial Statements
Note 2—Restatement of Previously Issued Financial Statements
On May 13 2021, the Audit Committee of the Company, in consultation with management, concluded that, because of a misapplication of the accounting guidance related to its public and private placement warrants to purchase shares of Class A common stock that the Company issued in October 2020 (the “Warrants”) and the forward purchase agreements, the Company’s previously issued financial statements for the Affected Periods should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Periods included in this Annual Report.
On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on October 23, 2020, the Company’s warrants and forward purchase agreements were accounted for as equity within the Company’s previously reported balance sheets. After discussion and evaluation, including with the Company’s independent registered public accounting firm and the Company’s audit committee, management concluded that the Warrants as well as the forward purchase agreements should be presented as liabilities with subsequent fair value remeasurement.
Historically, the Warrants and forward purchase agreements were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent
non-cash
changes in estimated fair value of the Warrants, based on our application of FASB ASC Topic
815-40,
Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC
815-40).
The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC
815-40
to the warrant agreement. The Company reassessed its accounting for Warrants issued on October 23, 2020 and its forward purchase agreements, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the Warrants and forward purchase agreements should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company’s statement of operations each reporting period.
Impact of the Restatement
The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Periods is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities.
 
    
As of December 31, 2020
 
    
As Previously
Reported
   
Restatement
Adjustment
   
As Restated
 
Balance Sheet
      
Total assets
   $ 404,063,677     $ —       $ 404,063,677  
  
 
 
   
 
 
   
 
 
 
Liabilities and stockholders’ equity
      
Total current liabilities
   $ 320,025     $ —       $ 320,025  
Deferred legal fees
     100,000       —         100,000  
Deferred underwriting commissions
     14,087,500       —         14,087,500  
Derivative liabilities
     —         49,674,170       49,674,170  
  
 
 
   
 
 
   
 
 
 
Total liabilities
     14,507,525       49,674,170       64,181,695  
Class A common stock, $0.0001 par value; shares subject to possible redemption
     384,556,150       (49,674,170     334,881,980  
Stockholders’ equity
      
Preferred stock - $0.0001 par value
     —         —         —    
Class A common stock - $0.0001 par value
     179       497       676  
Class B common stock - $0.0001 par value
     1,006       —         1,006  
Additional
paid-in-capital
     5,215,685       25,163,513       30,379,198  
Accumulated deficit
     (216,868     (25,164,010     (25,380,878
  
 
 
   
 
 
   
 
 
 
Total stockholders’ equity
     5,000,002       —         5,000,002  
Total liabilities and stockholders’ equity
   $ 404,063,677     $ —       $ 404,063,677  
  
 
 
   
 
 
   
 
 
 
    
Period From August 31, 2020 (Inception)

Through December 31, 2020
 
    
As Previously
Reported
   
Restatement
Adjustment
   
As Restated
 
Statement of Operations
      
Loss from operations
   $ (290,641   $ —       $ (290,641
Other (expense) income:
      
Change in fair value of derivative liabilities
     —         (24,193,170     (24,193,170
Financing costs - derivative liabilities
     —         (970,840     (970,840
Net gain from investments held in Trust Account
     78,522       —         78,522  
  
 
 
   
 
 
   
 
 
 
Total other (expense) income
     78,522       (25,164,010     (25,085,488
  
 
 
   
 
 
   
 
 
 
Loss before income tax expense
     (212,119     (25,164,010     (25,376,129
Income tax expense
     4,749       —         4,749  
Net loss
   $ (216,868   $ (25,164,010   $ (25,380,878
  
 
 
   
 
 
   
 
 
 
Basic and Diluted weighted-average Class A common shares subject to possible redemption outstanding
     38,473,726       (2,582,662     35,891,064  
  
 
 
   
 
 
   
 
 
 
Basic and Diluted net loss per Class A common shares subject to possible redemption
   $ —       $ —       $ —    
  
 
 
   
 
 
   
 
 
 
Basic and Diluted weighted-average
non-redeemable
Class A and Class B common shares outstanding
     10,646,616       1,585,845       12,232,461  
  
 
 
   
 
 
   
 
 
 
Basic and Diluted net loss per
non-redeemable
Class A and Class B common shares
   $ (0.02   $ 2.10     $ (2.08
  
 
 
   
 
 
   
 
 
 
 
    
Period From August 31, 2020 (Inception) Through

December 31, 2020
 
    
As Previously

Reported
   
Restatement

Adjustment
    
As Restated
 
Statement of Cash Flows
       
Net cash used in operating activities
     (491,670     —          (491,670
Net cash used in investing activities
     (402,500,000     —          (402,500,000
Net cash provided by financing activities
     404,071,303          404,071,303  
  
 
 
   
 
 
    
 
 
 
Net change in cash
   $ 1,079,633     $ —        $ 1,079,633  
  
 
 
   
 
 
    
 
 
 
In addition, the impact to the balance sheet dated October 23, 2020, filed on Form
8-K
on October 29, 2020 related to the impact of accounting for the public and private warrants and forward purchase agreements as liabilities at fair value resulted in a $25.5 million increase to the derivative liabilities line item at October 23, 2020 and offsetting decrease to the Class A common stock subject to possible redemption mezzanine equity line item. There is no change to total stockholders’ equity at the reported balance sheet date, however the accumulated
paid-in-capital,
accumulated deficit, and Class A common stock amounts did change for the financing costs.